Story
Keymed Biosciences Reports Positive Phase II Results for Sinusitis Drug CM512

Keymed Biosciences Inc. (02162.HK) announced that its self-developed Class 1 new drug, CM512, met all study endpoints in a Phase II clinical trial for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The company reported positive topline results following the completion of data unblinding and preliminary statistical analysis.
Key Trial Findings
The study demonstrated that CM512 was effective and well-tolerated across all tested dosage groups. According to the company's announcement, the drug showed both rapid onset and durable efficacy.
Key outcomes from the Phase II trial include:
- Rapid Efficacy: Patients experienced a reduction in nasal polyp size, significant improvement in nasal congestion, and restoration of smell function as early as the fourth week of treatment.
- Durable Response: A single injection provided a therapeutic effect that was sustained for six months. The change in Nasal Polyp Score (NPS) from baseline at 24 weeks was significantly superior to the placebo group.
- Safety Profile: CM512 exhibited a favorable safety and tolerability profile. The incidence of treatment-emergent adverse events (TEAEs) was comparable to the placebo group, and no serious adverse events were reported in the CM512 arms. The rate of anti-drug antibodies (ADA) was also noted as extremely low.
Path to Phase III
AdBased on these positive Phase II results, Keymed Biosciences is preparing to initiate a Phase III clinical study for CM512 in the treatment of CRSwNP. The company has established the dosing regimen for the upcoming pivotal trial.
The selected treatment plan for the Phase III study will be 300mg administered once every 24 weeks (Q24W), or once every six months. Keymed stated that more detailed data from the Phase II trial will be published in international academic journals or presented at future academic conferences.
Drug Profile and Context
CM512 is an investigational bispecific antibody designed to target both thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13), two key cytokines involved in Type 2 inflammation, which is a primary driver of CRSwNP. The positive trial data positions CM512 as a potential long-acting treatment option for this chronic inflammatory condition, which could offer a significant convenience advantage for patients if approved.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.